CLARITY PHARMACEUTICALS LIMITED (CU6)
Share Price Analysis and Chart

18/10/2024

1

Speculative Buy

$10.00

40.06%

Bell Potter observes the share price volatility for Clarity Pharmaceuticals, including positive clinical trial results, inclusion in ASX300 and then profit taking. From the $2.55 placement price in March 2024, investors have booked a handsome 250% at the September peak price of $8.97.

The analyst reiterates the company remains well funded with around $146m in cash and liquid assets, while the latest SECuRE trial shows recruitment is going well with safety and efficacy data in line with previous data. 

The Speculative Buy rating is maintained with $10 target price.

FORECAST
Bell Potter forecasts a full year FY24 dividend of 0.00 cents and EPS of minus -18.70 cents.
Bell Potter forecasts a full year FY25 dividend of 0.00 cents and EPS of minus -21.60 cents.

06/11/2024

1

Overweight

$8.48

18.77%

Wilsons assigns an Overweight rating to both Telix Pharmaceuticals ((TLX)) and Clarity Pharmaceuticals, with target prices of $25.00 and $8.48, respectively.

On an un-risked basis the analyst has a target price for Telix at $50 and and $21.14 for Clarity, citing promising growth in radiopharmaceutical diagnostics following the Centers for Medicare & Medicaid Services' 2025 final rule on pricing stability.

For Telix, the broker highlights the competitive advantage of Illucix in PSMA PET/CT scanning, with pricing stability set to support its market share until the launch of its next-generation TLX007-CDx in mid-2025.

Clarity is positioned to capture up to 30% of the PSMA PET/CT market with its 64Cu-SAR-bisPSMA tracer, leveraging potential clinical differentiation, including the ability to detect additional lesions.

FORECAST
Wilsons forecasts a full year FY24 dividend of 0.00 cents and EPS of minus -13.40 cents.
Wilsons forecasts a full year FY25 dividend of 0.00 cents and EPS of minus -17.10 cents.